Ragifilimab

拉格芙利单抗

Report date: 2022/07/04 19:38:02

Base Information

Drug NameRagifilimab
Drug Alias NameAnti-GITR-agonist-antibody-IncyteINCAGN-1876INCAGN-01876AGEN-1876CM-701
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionGlucocorticoid-induced tumor necrosis factor receptor-related protein agonists
TargetsGlucocorticoid-induced tumor necrosis factor receptor-related protein
Therapy Area/IndicationsNeoplasm MetastasisNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryBelgiumUnited StatesAustralia +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesAgenus IncLudwig Institute For Cancer Research
China Registration ClassN/A

Develop Information

Active CompaniesIncyte Biosciences International Sàrl
Inactive CompaniesN/A
Active IndicationsNeoplasm Metastasis
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A